HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elora Gupta Selected Research

Neoplasms (Cancer)

3/2004A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer.
9/2002Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Elora Gupta Research Topics

Disease

2Neoplasms (Cancer)
03/2004 - 09/2002
1Hemorrhage
11/2014
1Atrial Fibrillation
11/2014
1Stroke (Strokes)
11/2014
1Embolism (Embolus)
11/2014
1Myalgia
03/2004
1Exanthema (Rash)
03/2004
1Fatigue
03/2004
1Headache (Headaches)
03/2004
1Nausea
03/2004
1Arthralgia (Joint Pain)
03/2004

Drug/Important Bio-Agent (IBA)

1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
11/2014
1Warfarin (Coumadin)FDA LinkGeneric
11/2014
1AnticoagulantsIBA
11/2014
1apixabanIBA
11/2014
1N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl- 2,5- dioxo- 1- imidazolidinyl)butyl)- L- leucyl- N,3- dimethyl-L-ValinamideIBA
03/2004
1Pharmaceutical PreparationsIBA
03/2004
1Matrix Metalloproteinase InhibitorsIBA
03/2004
17-methylthiomethylpaclitaxel (BMS 184476)IBA
09/2002
1taxaneIBA
09/2002

Therapy/Procedure

1Therapeutics
11/2014
1Premedication
09/2002